Research library

B

grade

177Lu-FAP-2286 was well tolerated in patients with advanced solid tumors, with a recommended phase II dosage of 9.25 GBq.

RP2D for 177Lu-FAP-2286 monotherapy determined to be 9.25 GBq.

summary

B

grade

Overall survival was similar for both [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA I&T, but [177Lu]Lu-PSMA-617 showed greater biochemical response rates.

Median OS: [177Lu]Lu-PSMA I&T: 14 mo; [177Lu]Lu-PSMA-617: 15 mo; hazard ratio, 1.18; 95% CI, 0.79-1.78; P = 0.42.

summary

B

grade

Higher [68Ga]Ga-PSMA-11 SUVmean and SUVmean ratio may predict PSA response in [18F]FDG-positive mCRPC patients, but further research is needed.

PSA30 response in 44% of patients.

summary

B

grade

ARSi did not significantly enhance tumor absorbed doses in mCRPC patients receiving [177Lu]Lu-PSMA therapies. Larger studies are needed to confirm these findings.

2.1 ± 4.0 Gy/GBq vs 1.5 ± 1.7 Gy/GBq for [177Lu]Lu-PSMA-617, p=0.24

summary

A

grade

Capecitabine at 1000 mg/m² with Lu-PSMA is safe in heavily pre-treated mCRPC patients, but further research is needed to confirm efficacy.

MTD established at 1000 mg/m².

summary

B

grade

[225Ac]Ac-PSMA-617 shows promise for mCRPC with better survival and manageable toxicity, but further trials are needed.

PSA decline of >50% and disease control rate of 60% in [225Ac]Ac-PSMA-617 patients.

summary

A

grade

Lutetium Lu 177 vipivotide tetraxetan shows promise for treating mCRPC, but ongoing studies are needed to clarify its effectiveness in earlier stages of the disease.

Not reported in abstract.

summary

B

grade

177Lu-PSMA therapy can lead to rare but severe TMA, with unclear dose-response relationships. Early dosimetry may help identify patients at risk.

Cumulative renal absorbed dose ranged from 38.6 to 65.3 Gy.

summary

D

grade

International guidelines largely agree on using 177Lu-PSMA-617 for mCRPC, with a standard regimen of 7.4 GBq every 6 weeks.

7.4 GBq every 6 weeks for up to six cycles.

summary

C

grade

The study highlights the importance of screening commercial lily bulbs for latent viral infections and identifies potential genetic resistance mechanisms against LbV-1.

Infection rate of up to 45% in progeny plants.

summary

D

grade

Cabazitaxel may offer a more economical option compared to Lu-PSMA in treating mCRPC, despite Lu-PSMA showing better PSA response and progression-free survival metrics.

66% PSA response for Lu-PSMA vs 37% for cabazitaxel, p<0.0001.

summary

B

grade

Patients with mCRPC who received treatment after LuPSMA had a median overall survival of only 8.0 months, indicating a need for improved treatment strategies.

Median overall survival was 8.0 months (95% CI: 6.8-11.5).

summary

B

grade

This study highlights the importance of monitoring adverse events associated with [177Lu]Lu-PSMA-617, particularly in older patients who may be at higher risk.

870 adverse event reports associated with [177Lu]Lu-PSMA-617 in prostate cancer patients.

summary

D

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

B

grade

[177Lu]Lu-PSMA RLT shows comparable efficacy in younger prostate cancer patients compared to older patients, with a slightly better safety profile.

No significant differences were observed for PFS (P=0.882) and OS (P=0.17).

summary

B

grade

Single-time-point dosimetry for [¹⁷⁷Lu]Lu-PSMA-617 therapy shows a correlation with hematological decline, but further studies are needed to establish clinical significance.

Bone marrow absorbed dose (BMAD) at C1 was significantly correlated with red blood cells (RBC, ρ = -0.3) and hemoglobin (ρ = -0.26) decline.

summary

A

grade

177Lu-PSMA-I&T shows a median absorbed dose to kidneys of 0.35 ± 0.10 Gy/GBq, indicating a safety profile in patients with oligorecurrent hormone-sensitive prostate cancer.

AD to the kidneys was 0.35 ± 0.10 Gy/GBq.

summary

B

grade

This case highlights the importance of genetic testing for Lynch syndrome and suggests a potential association with pancreatic neuroendocrine tumors, but further studies are needed to confirm these findings.

Not reported in abstract.

summary

B

grade

This study highlights distinct adverse event profiles for enzalutamide, olaparib, and lutetium Lu-177 vipivotide tetraxetan in prostate cancer, with specific signals for anaemia and dry mouth.

ROR for anaemia with olaparib was 8.77.

summary

B

grade

Baseline hemoglobin levels below 10 g/dL and absolute neutrophil counts above 6500/µL are associated with shorter overall survival in patients with metastatic castration-resistant prostate cancer treated with lutetium-177-PSMA-617.

Median OS for the cohort was 13 months.

summary

A

grade

Concurrent [177Lu]Lu-PSMA-617 with EBRT and ADT appears safe and well tolerated in treatment-naïve N1M0 prostate cancer patients, but clinical efficacy requires further investigation.

No dose-limiting toxicity observed, n=14.

summary